NCT01537757View on ClinicalTrials.gov

A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Alzheimer's Disease
Interventions
DRUG

MK-8931

Single dose, administered as oral capsules

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01537757 - A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535]) | Biotech Hunter | Biotech Hunter